Animal virology

GeneTex Develops Recombinant Influenza Nucleoprotein Antibodies as Potential Diagnostics

Retrieved on: 
Monday, August 2, 2021
Influenza, Articles, Health, Orthomyxoviridae, Animal virology, Pandemic, Influenza A virus subtype H3N2, Swine influenza

The Company has now expanded its existing influenza virus catalog with the release of a series of recombinant rabbit monoclonal antibodies that broadly detect the nucleoproteins (NPs) of influenza A and influenza B strains.

Key Points: 
  • The Company has now expanded its existing influenza virus catalog with the release of a series of recombinant rabbit monoclonal antibodies that broadly detect the nucleoproteins (NPs) of influenza A and influenza B strains.
  • Both influenza A and influenza B viruses are responsible for potentially lethal human disease and epidemics, with influenza A associated with pandemics.
  • There are three recombinant antibodies ( GTX636199 [HL1078] , GTX636247 [HL1089] , GTX636318 [HL1103] ) for influenza A NP and three ( GTX636099 [HL1068] , GTX636100 [HL1069] , GTX636194 [HL1073] ) for influenza B NP.
  • These recombinant influenza NP antibodies mark another milestone in GeneTex's efforts to support research combating pathogenic viruses, both endemic and emerging.

Oragenics Enters into Licensing Agreement with the National Research Council of Canada, to Pursue the Rapid Development of Next-Generation SARS-CoV-2 Vaccines

Retrieved on: 
Tuesday, July 27, 2021
Biotechnology, Infectious diseases, Health, Pharmaceutical, Clinical trials, Coronaviridae, Articles, Sarbecovirus, Health, Zoonoses, Animal virology, Coronavirus, Severe acute respiratory syndrome coronavirus 2, Severe acute respiratory syndrome, Pandemic, Vaccine, COVID-19

Oragenics, Inc. (NYSE American: OGEN) today announced it has entered into a licensing agreement with the National Research Council of Canada (NRC) that will enable Oragenics to pursue the rapid development of next-generation vaccines against the SARS-CoV-2 virus and its variants.

Key Points: 
  • Oragenics, Inc. (NYSE American: OGEN) today announced it has entered into a licensing agreement with the National Research Council of Canada (NRC) that will enable Oragenics to pursue the rapid development of next-generation vaccines against the SARS-CoV-2 virus and its variants.
  • The NRC technologies, developed with support from the NRCs Pandemic Response Challenge Program, will expedite the evaluation of SARS-CoV-2 antigen candidates in preclinical and clinical studies.
  • Oragenics, Inc. is a development-stage company dedicated to fighting infectious diseases including coronaviruses and multidrug-resistant organisms.
  • Its lantibiotics program features a novel class of antibiotics against infectious diseases that have developed resistance to commercial antibiotics.

Medigus: Polyrizon’s innovative proprietary technology found effective against coronavirus in a pre-clinical study

Retrieved on: 
Friday, July 23, 2021
Animal virology, Coronavirus

OMER, Israel, July 23, 2021 (GLOBE NEWSWIRE) --  Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies and electric vehicle and charging solutions, today announced that Polyrizon Ltd., a privately held company (which Medigus owns 33.24% of its share capital) engaged in developing highly differentiated biological gels for the purpose of protecting patients against biological threats and external pathogens, reported pre-clinical data from its previously announced pre-clinical study showing that its proprietary technology has the potential to reduce the risk of an infection with Human coronavirus and may also prevent COVID-19. Polyrizon develops an innovative technology, designed to safely prevent allergens and virus intrusion through the upper airways and eye cavities. Polyrizon’s technology is comprised of a bio-gel that is applied topically, and can be formulated both for wet and dry administration.

Key Points: 
  • Polyrizon develops an innovative technology, designed to safely prevent allergens and virus intrusion through the upper airways and eye cavities.
  • Polyrizons technology is comprised of a bio-gel that is applied topically, and can be formulated both for wet and dry administration.
  • Polyrizons cell-culture study was conducted in Israel and lasted one month.
  • The trial tested a number of different formulations of its highly differentiae biological gel comparing to controlled groups for protection against coronavirus, and screening several new formulations designed to prevent coronavirus from effecting epithelial cells.

Protect Yourself: Summer is Peak Season for Mosquito Activity

Retrieved on: 
Thursday, July 22, 2021
Family, Health, Other Consumer, Consumer, Infectious diseases, Children, General Health, Viral encephalitis, Veterinary medicine, Arthropods, Animal virology, Medical specialties, Biological weapons, Culicidae, Insect control, Mosquito-borne disease, Mosquito, Eastern equine encephalitis, Jamestown Canyon encephalitis

Summer is peak season for the worlds deadliest animal the mosquito and news reports across the country indicate that we are experiencing one of the heaviest mosquito seasons in a while.

Key Points: 
  • Summer is peak season for the worlds deadliest animal the mosquito and news reports across the country indicate that we are experiencing one of the heaviest mosquito seasons in a while.
  • The most prevalent mosquito-borne disease in the U.S., it has been detected in all 48 continental states, D.C. and Puerto Rico, peaking in late summer and early fall.
  • Eastern Equine Encephalitis (EEE) is a rare disease caused by a virus spread through the bite of an infected mosquito.
  • For help controlling mosquito populations in your yard or around your property, contact a licensed pest control professional .

First Trust Senior Floating Rate 2022 Target Term Fund Decreases its Monthly Common Share Distribution to $0.0078 Per Share for August

Retrieved on: 
Tuesday, July 20, 2021
Other Professional Services, Professional services, Finance, Finance, Money, Economy, Financial ratios, Animal virology, Feline immunodeficiency virus, Lentiviruses, Rate of return

First Trust Senior Floating Rate 2022 Target Term Fund (the "Fund") (NYSE: FIV) has decreased its regularly scheduled monthly common share distribution to $0.0078 per share from $0.0103 per share. The distribution will be payable on August 16, 2021, to shareholders of record as of August 3, 2021. The ex-dividend date is expected to be August 2, 2021. The monthly distribution information for the Fund appears below.

Key Points: 
  • First Trust Senior Floating Rate 2022 Target Term Fund (the "Fund") (NYSE: FIV) has decreased its regularly scheduled monthly common share distribution to $0.0078 per share from $0.0103 per share.
  • "Managed Assets" means the total asset value of the Fund minus the sum of its liabilities, other than the principal amount of borrowings.
  • As a result, based on current market conditions and expectations, the Fund believes that it is unlikely to achieve its objective of returning $9.85 per Common Share upon its termination.
  • As a result of these actions, investors should anticipate periodic reductions in the Fund's distribution per share going forward.

iBio Reports Successful Preclinical Immunization Studies with Next-Gen Nucleocapsid COVID-19 Vaccine Candidate

Retrieved on: 
Thursday, July 15, 2021
Medical specialties, Zoonoses, Medicine, Branches of biology, Animal virology, Virology, Coronavirus, COVID-19, Severe acute respiratory syndrome coronavirus 2, Vaccine, Antigen

BRYAN, Texas, July 15, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (iBio or the Company), a biotech innovator and biologics contract manufacturing organization, today announced that preclinical studies of IBIO-202, its subunit vaccine candidate that targets the nucleocapsid protein (N protein) of SARS-CoV-2, demonstrated a robust, antigen-specific, memory T-cell response.

Key Points: 
  • BRYAN, Texas, July 15, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (iBio or the Company), a biotech innovator and biologics contract manufacturing organization, today announced that preclinical studies of IBIO-202, its subunit vaccine candidate that targets the nucleocapsid protein (N protein) of SARS-CoV-2, demonstrated a robust, antigen-specific, memory T-cell response.
  • Notably, the SARS-CoV-2 N protein shares substantial sequence conservation with the nucleocapsid of other coronaviruses.
  • The IBIO-202 immunization data are consistent with that, as a strong, cytotoxic, memory T-cell response was seen, rather than an inflammatory response.
  • iBio is developing proprietary products which include biopharmaceuticals for the treatment of cancers, as well as fibrotic and infectious diseases.

2021 Report on Seasonal Influenza Vaccines - Market is Expected to Expand Over Next 10 Years - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 8, 2021
Infectious diseases, Pharmaceutical, Health, Medical specialties, Vaccination, Health care, Vaccines, Influenza vaccines, Animal virology, Influenza, Influenza vaccine, Live attenuated influenza vaccine, Flu season, Vaccine, Sanofi

The "Disease Analysis: Seasonal Influenza Vaccines" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Disease Analysis: Seasonal Influenza Vaccines" report has been added to ResearchAndMarkets.com's offering.
  • Two types of influenza virus are predominant in humans, types A and B, which circulate annually between late fall and early spring, causing seasonal epidemics.
  • Three major manufacturers dominate the seasonal influenza vaccines market, namely GlaxoSmithKline, Seqirus, and Sanofi, with 2020 vaccines sales of $1,023m, $952m (June 2019 to June 2020), and $2,953m, respectively.
  • Additionally, AstraZeneca's FluMist QIV has recovered its footing in the influenza market, matching its previous peak sales of $295m.

Gliknik Inc. Raises $11.5 Million in Series C Financing

Retrieved on: 
Thursday, June 24, 2021
Research, Infectious diseases, Genetics, Clinical trials, Biotechnology, Health, Pharmaceutical, Science, Oncology, Animal virology, Feline immunodeficiency virus, Lentiviruses, Placebo-controlled study, Immunology, Health sciences, Health, Medicine

Gliknik Inc. , an immunology company dedicated to patients with cancer and autoimmune disorders, today announced that it has successfully completed an $11.5 million Series C Preferred Stock financing.

Key Points: 
  • Gliknik Inc. , an immunology company dedicated to patients with cancer and autoimmune disorders, today announced that it has successfully completed an $11.5 million Series C Preferred Stock financing.
  • First In Ventures (FIV) led the Series C with SAISO Partners and affiliates of RDA Ventures and Garden Street Holdings also participating.
  • We believe that Gliknik has created several potential best-in-class mid-stage assets, said Scott Roth, managing partner of FIV.
  • Funding will help advance Gliknik clinical and pre-clinical programs, including:
    A randomized double-blind, placebo-controlled phase 2 study of Gliknik immuno-oncology compound biropepimut-S , which is nearing completion.

Algenex and FATRO announce positive CVMP opinion for CrisBio-based vaccine for Rabbit Viral Haemorrhagic Disease

Retrieved on: 
Monday, June 21, 2021
Medical specialties, Medicine, Health sciences, Animal virology, Rabbit hemorrhagic disease, RHD, Pandemics, Vaccination, Committee for Medicinal Products for Veterinary Use, Vaccine, Virus

The final decision of the European Commission on the marketing authorisation of FATROVAX RHD is expected in the coming months.

Key Points: 
  • The final decision of the European Commission on the marketing authorisation of FATROVAX RHD is expected in the coming months.
  • Rabbit Haemorrhagic Disease Virus, with its variants RHDV and RHDV2, is endemic in most parts of the world, and causes a highly contagious, acute and fatal disease.
  • The positive opinion of the EMAs CVMP represents a significant regulatory validation for Algenexs CrisBio technology and a major milestone for the Company.
  • FATRO invests continuously in research in the ethical drugs and veterinary vaccines sectors, with the aim of developing new products and production technologies.

VBI Vaccines to Present at Upcoming Scientific Conferences

Retrieved on: 
Thursday, June 17, 2021
Research, Infectious diseases, FDA, Clinical trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Medical specialties, Clinical medicine, Health, Vaccines, Infectious causes of cancer, Viral diseases, Virology, Animal virology, Hepatitis, Vaccine, Virus, Coronavirus, Hepatitis B, VBI’s 3-Antigen Hepatitis B Vaccine, VBI Vaccines Inc., HEPATITIS B, VBI’S 3-ANTIGEN HEPATITIS B VACCINE, VBI VACCINES INC.

Hepatitis B is one of the worlds most significant infectious disease threats with more than 290 million people infected globally.

Key Points: 
  • Hepatitis B is one of the worlds most significant infectious disease threats with more than 290 million people infected globally.
  • To learn more about VBIs 3-Antigen Hepatitis B vaccine candidate visit: https://www.vbivaccines.com/sci-b-vac/
    VBI Vaccines Inc. (VBI) is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease.
  • VBI is committed to targeting and overcoming significant infectious diseases, including hepatitis B, coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers including glioblastoma (GBM).
  • VBI is headquartered in Cambridge, Massachusetts, with research operations in Ottawa, Canada, and a research and manufacturing site in Rehovot, Israel.